0001562180-21-006476.txt : 20211015 0001562180-21-006476.hdr.sgml : 20211015 20211015183345 ACCESSION NUMBER: 0001562180-21-006476 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211015 FILED AS OF DATE: 20211015 DATE AS OF CHANGE: 20211015 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Linetsky David CENTRAL INDEX KEY: 0001776729 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38977 FILM NUMBER: 211326987 MAIL ADDRESS: STREET 1: C/O PHREESIA, INC. STREET 2: 432 PARK AVENUE S., 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Phreesia, Inc. CENTRAL INDEX KEY: 0001412408 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0131 BUSINESS ADDRESS: STREET 1: 434 FAYETTEVILLE ST. STREET 2: SUITE 1400 CITY: RALEIGH STATE: NC ZIP: 27601 BUSINESS PHONE: 646-747-9959 MAIL ADDRESS: STREET 1: 434 FAYETTEVILLE ST. STREET 2: SUITE 1400 CITY: RALEIGH STATE: NC ZIP: 27601 FORMER COMPANY: FORMER CONFORMED NAME: Phreesia Inc DATE OF NAME CHANGE: 20070914 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2021-10-15 false 0001412408 Phreesia, Inc. PHR 0001776729 Linetsky David C/O PHREESIA, INC. 434 FAYETTEVILLE ST., SUITE 1400 RALEIGH NC 27601 false true false false SVP, Life Sciences Common Stock 2021-10-15 4 M false 5452.00 4.71 A 145840.00 D Common Stock 2021-10-15 4 S false 5452.00 65.3584 D 140388.00 D Stock Option 4.71 2021-10-15 4 M false 5452.00 0.00 D 2028-01-30 Common Stock 5452.00 11851.00 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.67 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 25% of this option shall vest and become exercisable on January 31, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Allison Hoffman, as Attorney-in-Fact for David Linetsky 2021-10-15